Biofrontera Inc. has reported an impressive financial performance for the second quarter of 2026, marking it as the strongest Q2 and first half in the company's operational history as an independent U.S. entity. This period saw net product revenue climb to $12 million, reflecting a substantial 32.9% year-over-year increase, primarily propelled by a 30% surge in Ameluz unit sales and a price adjustment implemented in late 2025. The gross margin expanded significantly to 80% from 71% in the prior year, a direct result of a restructured cost base following the 2025 strategic transaction. Furthermore, the company demonstrated strong expense discipline, reducing its adjusted EBITDA loss to a mere $200,000, a remarkable $5 million improvement from a $5.1 million loss in the same quarter last year.
Amidst its financial triumphs, Biofrontera is navigating regulatory and intellectual property challenges while aggressively pursuing pipeline expansion. The International Trade Commission issued an exclusion order for the RhodoLED XL lamp due to patent infringement concerns, effective July 7, 2026. However, this order does not impact the majority of the company's installed base of original BF-RhodoLED lamps. Biofrontera is actively developing a modified, non-infringing version of the XL lamp, with an estimated remediation cost of $500,000, and is contesting the ITC's decision. Concurrently, the company is preparing for the potential launch of Ameluz for superficial basal cell carcinoma (sBCC) in Q1 2027, pending an FDA approval decision by September 28, 2026. Additionally, a supplemental New Drug Application is planned for late Q3 2026 to expand Ameluz's label for actinic keratosis (AK) to other body areas, with anticipated approval in Q3 2027. Clinical development for moderate to severe acne is also progressing, with Phase 2B results showing significant reduction in inflammatory lesions.
The company's commercial strategy, as highlighted by Chief Commercial Officer George Jones, is yielding positive results. Order counts increased by 18.6% and average tubes per order rose by 10% in the first half of 2026 compared to the previous year. A high reorder rate of 81% from large customers, with a 41% increase in Ameluz volume, underscores the effectiveness of sales efforts. New account growth remained stable, and inside sales initiatives successfully generated thousands of Ameluz tubes from untapped markets and vacant territories. Financially, the company continues to manage its capital prudently, reducing operating cash use by 76% in the first half of 2026. Despite a 'going concern' qualification in its financial statements, Biofrontera is confident in achieving cash flow breakeven in 2026 through continued revenue growth, a $1 million milestone payment from the XEPI divestiture, and potential credit facilities if necessary. The company remains dedicated to its mission of improving patients' lives through innovative skin cancer treatments.
The concerted efforts by Biofrontera in strengthening its commercial framework, diligently managing its finances, and tenaciously pursuing new medical indications demonstrate a clear path toward sustainable growth and a deeper impact on public health. This strategic approach, combining operational excellence with a commitment to innovation, embodies a forward-looking vision for success and service to both patients and shareholders.
